Kovack Advisors’s Northwest Biotherapeutics NWBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-10,000
Closed -$6K – 775
2022
Q1
$6K Buy
+10,000
New +$6K ﹤0.01% 719
2021
Q3
– Sell
-25,000
Closed -$37K – 775
2021
Q2
$37K Buy
+25,000
New +$37K ﹤0.01% 663
2014
Q1
– Sell
-11,978
Closed -$45K – 97
2013
Q4
$45K Sell
11,978
-738
-6% -$2.86K 0.24% 57
2013
Q3
$43K Sell
12,716
-4,229
-25% -$14.7K 0.22% 53
2013
Q2
$57K Buy
+16,945
New +$61.4K 0.34% 45

Other funds holding NWBO

Kovack Advisors's NWBO Position: Q2 2022 in Review

Kovack Advisors sold out of Northwest Biotherapeutics (NWBO) in Q2 2022, closing a stake of 10,000 shares — an estimated $6K sold.

Kovack Advisors first reported a position in NWBO in Q2 2013 and held it in 5 quarters. The position peaked at $57K in Q2 2013. 14 funds tracked by Wall St. Rank hold NWBO as of Q2 2022.

  • Kovack Advisors reported no remaining Northwest Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Kovack Advisors sold 10,000 Northwest Biotherapeutics shares in Q2 2022, an estimated $6K.
  • Kovack Advisors first reported a position in Northwest Biotherapeutics in Q2 2013 and held it in 5 quarters.
  • Kovack Advisors's Northwest Biotherapeutics position peaked at $57K in Q2 2013.
  • 14 funds tracked by Wall St. Rank held Northwest Biotherapeutics as of Q2 2022.

Based on Kovack Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.